Recently, the first ctDNA screening test (cobas® EGFR Mutation Test v2, Roche, Switzerland) for molecular analysis of ctDNA in metastatic NSCLC patients in whom mutation screening was impossible in tumor tissue was approved by the FDA. This evidence concerns the gene EGFR and non-small cell lung carcinoma.